Award

Alanyl-glutamine supplementation of standard treatment for C. difficile infection

Description: PROJECT NARRATIVE C. difficile infection (CDI) is the most common cause of antibiotic-induced diarrhea. Anti-C. difficile antibiotic is associated with recurrent CDI. This proposal will test whether nutritional supplementation with alanyl-glutamine, in addition to standard treatment, can reduce intestinal inflammation, recurrence, and deaths from CDI.
Funding type: research
Funder scheme: R01
Start date: 2020-07-13
End date: 2026-06-30
Field: Medicine
Funded outputs count: 20
Funder award ID: R01AI145322
OpenAlex ID: G5058619045
2026 · Garrison P Wright, Nina Gu, et al. · Open Forum Infectious Diseases
2026 · Mônica J. Rodrigues-Jesus, Maria L.G.S. Morais, et al. · Journal of Infection · 1
2026 · Rahim A. Burdette, Caroline C. Whitt, et al. · Microorganisms · 1
2025 · Medical Clinics of North America
2025 · Deiziane V. S. Costa, Beatriz Thomasi, et al. · Nature Reviews Gastroenterology & Hepatology · 10
2025 · Joseph D. K. Nguyen, Kibret G. Yohannes, et al. · Therapeutic Advances in Gastroenterology · 3
2025 · Rahim A. Burdette, Caroline C. Whitt, et al. · ACG Case Reports Journal · 3
2025 · Jae H. Shin, Jasmine Y. Jackson-Akers, et al. · Medical Clinics of North America · 2
2023 · Maria-Jose Fernandez-Cotarelo, Jasmine Y. Jackson-Akers, et al. · European journal of medical research · 25
2022 · Gregory R. Madden, William A. Petri, et al. · Antimicrobial Agents and Chemotherapy · 19
2022 · Emma C. Phillips, Cirle A. Warren, et al. · Antimicrobial Agents and Chemotherapy · 16